227 related articles for article (PubMed ID: 21586562)
1. Angiopoietin-like 2, a circadian gene, improves type 2 diabetes through potentiation of insulin sensitivity in mice adipocytes.
Kitazawa M; Nagano M; Masumoto KH; Shigeyoshi Y; Natsume T; Hashimoto S
Endocrinology; 2011 Jul; 152(7):2558-67. PubMed ID: 21586562
[TBL] [Abstract][Full Text] [Related]
2. Angiopoietin Like Protein 2 (ANGPTL2) Promotes Adipose Tissue Macrophage and T lymphocyte Accumulation and Leads to Insulin Resistance.
Sasaki Y; Ohta M; Desai D; Figueiredo JL; Whelan MC; Sugano T; Yamabi M; Yano W; Faits T; Yabusaki K; Zhang H; Mlynarchik AK; Inoue K; Mizuno K; Aikawa M
PLoS One; 2015; 10(7):e0131176. PubMed ID: 26132105
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
[TBL] [Abstract][Full Text] [Related]
5. Perivascular adipose tissue-secreted angiopoietin-like protein 2 (Angptl2) accelerates neointimal hyperplasia after endovascular injury.
Tian Z; Miyata K; Tazume H; Sakaguchi H; Kadomatsu T; Horio E; Takahashi O; Komohara Y; Araki K; Hirata Y; Tabata M; Takanashi S; Takeya M; Hao H; Shimabukuro M; Sata M; Kawasuji M; Oike Y
J Mol Cell Cardiol; 2013 Apr; 57():1-12. PubMed ID: 23333801
[TBL] [Abstract][Full Text] [Related]
6. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
Park SY; Shin HK; Lee JH; Kim CD; Lee WS; Rhim BY; Hong KW
J Pharmacol Exp Ther; 2009 May; 329(2):571-9. PubMed ID: 19221061
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-α increases angiopoietin-like protein 2 gene expression by activating Foxo1 in 3T3-L1 adipocytes.
Zheng JY; Zou JJ; Wang WZ; Feng XY; Shi YY; Zhao Y; Jin G; Liu ZM
Mol Cell Endocrinol; 2011 Jun; 339(1-2):120-9. PubMed ID: 21501655
[TBL] [Abstract][Full Text] [Related]
8. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression.
Kanatani Y; Usui I; Ishizuka K; Bukhari A; Fujisaka S; Urakaze M; Haruta T; Kishimoto T; Naka T; Kobayashi M
Diabetes; 2007 Mar; 56(3):795-803. PubMed ID: 17327450
[TBL] [Abstract][Full Text] [Related]
9. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Nakano S; Inada Y; Masuzaki H; Tanaka T; Yasue S; Ishii T; Arai N; Ebihara K; Hosoda K; Maruyama K; Yamazaki Y; Shibata N; Nakao K
Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1213-22. PubMed ID: 17190905
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes.
Pan Y; Shu JL; Gu HF; Zhou DC; Liu XL; Qiao QY; Fu SK; Gao FH; Jin HM
Mol Cell Endocrinol; 2013 Mar; 367(1-2):116-23. PubMed ID: 23313788
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of RyR3 enhances adiponectin expression through an atf3-dependent pathway.
Tsai SH; Chang EY; Chang YC; Hee SW; Tsai YC; Chang TJ; Chuang LM
Endocrinology; 2013 Mar; 154(3):1117-29. PubMed ID: 23389954
[TBL] [Abstract][Full Text] [Related]
12. β-Carotene accumulation in 3T3-L1 adipocytes inhibits the elevation of reactive oxygen species and the suppression of genes related to insulin sensitivity induced by tumor necrosis factor-α.
Kameji H; Mochizuki K; Miyoshi N; Goda T
Nutrition; 2010; 26(11-12):1151-6. PubMed ID: 20097535
[TBL] [Abstract][Full Text] [Related]
13. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Combs TP; Wagner JA; Berger J; Doebber T; Wang WJ; Zhang BB; Tanen M; Berg AH; O'Rahilly S; Savage DB; Chatterjee K; Weiss S; Larson PJ; Gottesdiener KM; Gertz BJ; Charron MJ; Scherer PE; Moller DE
Endocrinology; 2002 Mar; 143(3):998-1007. PubMed ID: 11861525
[TBL] [Abstract][Full Text] [Related]
14. Regulation effects of TZQ-F on adipocyte differentiation and insulin action.
Nan Xia J; Qin Zhang D; Du J; Wen J
J Ethnopharmacol; 2013 Nov; 150(2):692-9. PubMed ID: 24095827
[TBL] [Abstract][Full Text] [Related]
15. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Iwai M; Kanno H; Inaba S; Senba I; Sone H; Nakaoka H; Horiuchi M
Am J Hypertens; 2011 Feb; 24(2):169-74. PubMed ID: 20847723
[TBL] [Abstract][Full Text] [Related]
16. Gly-Ala-Gly-Val-Gly-Tyr, a novel synthetic peptide, improves glucose transport and exerts beneficial lipid metabolic effects in 3T3-L1 adipoctyes.
Kim ED; Kim E; Lee JH; Hyun CK
Eur J Pharmacol; 2011 Jan; 650(1):479-85. PubMed ID: 20951125
[TBL] [Abstract][Full Text] [Related]
17. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes.
Zhou J; Zhou S
Eur J Pharmacol; 2010 Dec; 649(1-3):390-7. PubMed ID: 20868663
[TBL] [Abstract][Full Text] [Related]
18. Cyclolepis genistoides D. Don (palo azul) promotes differentiation of adipocytes and regulates adipokine expression.
Sato H; Ishikawa M; Funaki A; Kimura Y; Yoshida H; Fukata H; Hasegawa H; Ueno K
Nutr Res; 2013 Nov; 33(11):922-31. PubMed ID: 24176232
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
20. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
